SCHEMBL5849338

SCHEMBL5849338

CCc1cc2c(N3CCN(C(=O)CC(F)(F)F)CC3C)ncnc2s1

nearest known ligand 0.72

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 7/20 0.72
MEN1 O00255 10/20 0.50
KMT2A Q03164 5/20 0.47
ALDH1A1 P00352 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
TSHR P16473 2/20 0.46
HRH4 Q9H3N8 1/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 3/20 0.45
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5849347 0.86 MEN1 (0.58) P2RY12MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5848809 0.86 MEN1 (0.58) P2RY12MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL7062060 0.86 MEN1 (0.58) P2RY12MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5851381 0.84 P2RY12 (1.00) P2RY12MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5848808 0.83 P2RY12 (0.73) P2RY12MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5849381 0.83 P2RY12 (0.73) P2RY12MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5848691 0.83 P2RY12 (0.73) P2RY12MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5849298 0.83 P2RY12 (0.52) P2RY12MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5849512 0.77 P2RY12 (0.85) P2RY12MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL7058405 0.75 MEN1 (0.57) P2RY12MEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115741-B2 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds ALEXION PHARMACEUTICALS, INC. 2006-10-03 US disclosed
US-20030153556-A1 Piperazine and homopiperazine compounds MILLENNIUM PHARMACEUTICALS, INC. 2003-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153556-A1 Piperazine and homopiperazine compounds HAMP, MPL, F2 P2RY12 111/4885MEN1 2603/4885KMT2A 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.